Importance Comparative real-world effectiveness studies of initial disease-modifying
treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include …

Importance Therapeutic options for patients with secondary progressive multiple sclerosis
(SPMS) are limited. Objective To analyze disability progression in patients with SPMS …

Background Despite positive results from phase II and observational studies, Rituximab
(RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used …

Objective: To compare treatment effectiveness and persistence in relapsing-remitting
multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or …

Importance Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B
cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared …

Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS).
More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo …

Background Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin
lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. Objectives …

Background B-cell depleting therapies are highly efficacious in relapsing-remitting multiple
sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no …

Background Rituximab (RTX) and other anti-CD20 therapies are increasingly used as
disease modifying treatments (DMTs) in MS. However, data on reasons to interrupt …

Importance As disease-modifying treatment options for multiple sclerosis increase,
comparisons of the options based on real-world evidence may guide clinical decision …